HERON THERAPEUTICS, INC. /DE/ Income Statement
HRTX|2 years of annual SEC 10-K data (FY2016-FY2017)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
HERON THERAPEUTICS, INC. /DE/ reported $1M in revenue and $98M in net loss for FY2017. Revenue increased 0.0% from FY2016 to FY2017.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2017 | FY2016 |
|---|---|---|
| Revenue | $1.3M | $1.3M |
| Cost of Revenue | $35.0K | $35.0K |
| Gross Profit | $2.4M | - |
| SG&A Expense | $18.4M | $11.0M |
| R&D Expense | $61.2M | $54.8M |
| Operating Income | -$96.9M | -$74.6M |
| Interest Expense | $958.0K | $887.0K |
| Income Tax | $0 | $0 |
| Net Income | -$97.6M | -$76.4M |
| EPS (Diluted) | -$2.95 | -$2.87 |
| Shares Outstanding | 39.4K | 36.1M |
| Gross Margin | 191.2% | - |
| Operating Margin | -7578.2% | -5829.6% |
| Profit Margin | -7630.3% | -5970.8% |